Product

aflibercept

Aliases

BAY86-5321, Eylea®, EYLEA®

5 clinical trials

7 indications

Indication

Age-related macular degeneration

Indication

Age-Related Macular Degeneration

Indication

Retinopathy of Prematurity

Indication

Wet Age-Related Macular Degeneration

Indication

Diabetic Macular Edema

Indication

Type 1 Diabetes Mellitus

Indication

Type 2 Diabetes Mellitus

Clinical trial

Status: Terminated, Estimated PCD: 2017-01-01

Clinical trial

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Status: Completed, Estimated PCD: 2023-06-28

Clinical trial

A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Status: Completed, Estimated PCD: 2021-05-14

Clinical trial

Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Status: Completed, Estimated PCD: 2022-08-18

Clinical trial

A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema

Status: Active (not recruiting), Estimated PCD: 2022-05-30